Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To assess 12-month outcomes of prostate artery embolization (PAE) using N-butyl cyanoacrylate (NBCA) glue in patients with incapacitating lower-urinary-tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
Materials And Methods: Retrospective single-center observational study of patients evaluated 12 months after PAE done in 2018-2023 using methacryloxysulfolane-NBCA mixed with ethiodized oil. Glue injection was under free- or blocked-flow conditions, depending on artery size and real-time assessment of penetration. Both distal embolization and proximal prostatic-artery occlusion were achieved without filling of collaterals. The 12-month outcomes were the International Prostate Symptom Score (IPSS) and associated Quality-of-Life score (IPSS-QoL), prostate volume, International Index of Erectile Function form 5 (IIEF5), and prostate-specific antigen (PSA) level.
Results: A total of 186 patients with a mean age of 67.5 ± 6.0 years were included. All procedures were technically successful. Minor adverse events occurred in 35/186 (18.8%) patients. There were no major complications. At 12 months, significant improvements vs baseline were noted for the IPSS (10 ± 6.6 vs 20.1 ± 6.4, p = 0.0001), IPSS-QoL (2.2 ± 1.6 vs 5.1 ± 0.9, p = 0.0001), and prostate volume (81.1 ± 47.0 mL vs 118.1 ± 67.4 mL, p = 0.0001). The IIEF5 and PSA levels were not significantly different at 12 months vs baseline (16.2 ± 7.2 vs 15.8 ± 6.9, p = 0.814; and 4.9 ± 3.3 vs 4.8 ± 4.2, p = 0.286; respectively).
Conclusions: Our data support the feasibility, safety, and sustained effectiveness at 12 months of PAE with NBCA to treat BPH-related LUTS.
Key Points: Question NBCA glue may have advantages over other agents for prostatic artery embolization in BPH, but data on long-term outcomes are scarce. Findings Prostatic artery embolization using glue led to significant decreases in the International Prostate Symptoms Score, quality of life score, and prostate volume at 12-month follow-up. Clinical relevance NBCA glue for prostatic artery embolization in patients with symptomatic BPH is safe and provides sustained symptom relief for at least one year.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00330-025-11983-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.
Heart
September 2025
Department of Cardiology, University of Ulsan College of Medicine, Seoul, Korea (the Republic of)
Objective: The impact of off-label underdosing of direct oral anticoagulants (DOACs) on clinical outcomes in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains unclear.
Methods: The EPIC-CAD trial (Edoxaban vs Edoxaban with antiPlatelet agent In patients with atrial fibrillation and Chronic stable Coronary Artery Disease) randomised patients with AF and stable CAD to receive either edoxaban monotherapy or dual antithrombotic therapy (edoxaban plus single antiplatelet agent). Off-label underdosing was defined as low-dose edoxaban (30 mg once daily) without standard criteria for dose reduction.
Headache Outcomes After Treatment of Cerebral Arteriovenous Malformations: A Systematic Review and Meta-Analysis with Clinical Implications.
Cardiol Rev
September 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Arteriovenous malformations (AVMs) are abnormal connections between cerebral arteries and veins that lack an intervening capillary bed. Brain AVMs affect approximately 0.1% of the population and are diagnosed in 1.
View Article and Find Full Text PDFRight coronary artery takeoff plane and implications for brachiocephalic interventions and next generation transcatheter aortic valve intervention embolic protection devices.
J Invasive Cardiol
September 2025
Newark Beth Israel Medical Center, Newark, New Jersey.
Objectives: The authors hypothesized that the origin of the right coronary artery (RCA) is a direct continuation of the major aortic arch branches (MAAB) takeoff plane, which may have implications for brachiocephalic interventions and next generation transcatheter aortic valve intervention (TAVI) embolic protection devices (EPDs).
Methods: In this single-center, retrospective, cross-sectional study, the authors analyzed computed tomographic angiography (CTA) images from 92 patients undergoing TAVI evaluation to determine the spatial relationship between the origin of the RCA and the MAAB takeoff plane. Patients with prior cardiothoracic or aortic interventions and those with anomalous RCA origin were excluded.
Acquired uterine arteriovenous malformation: efficacy of the use of absorbable haemostatic gelatin in uterine artery embolisation.
Emerg Radiol
September 2025
Monash Imaging, Monash Health, VIC, Clayton, Australia.
Purpose: To evaluate the efficacy and complications of absorbable haemostatic gelatin uterine artery embolisation for symptomatic acquired uterine arterio-venous malformation (UAVM).
Methods: All the adult female patients who had acute urogenital bleeding due to UAVM confirmed on ultrasound and received uterine artery embolisation (UAE) for UAVM in a tertiary institution between January 2000 and October 2024 were included. Patients who had UAE for other causes were excluded.
The evaluation of non-contrast MRA using a modified balanced steady state free precession technique in the follow-up of renal artery aneurysm after embolotherapy.
Abdom Radiol (NY)
September 2025
Peking University First Hospital, Beijing, China.
Purpose: To evaluate the feasibility and clinical utility of non-contrast magnetic resonance angiography (NC-MRA) using a modified balanced steady-state free precession (b-SSFP) technique combined with arterial spin labeling (ASL) for post-embolotherapy follow-up of renal artery aneurysms (RAAs), with digital subtraction angiography (DSA) as the reference standard.
Method: A total of 57 patients with RAAs underwent embolotherapy between June 2013 and July 2024. Among them, 15 RAAs from 14 patients underwent post-embolization surveillance with the NC-MRA and DSA.